Menopausal hormone therapy and dementia
- PMID: 37380188
- DOI: 10.1136/bmj.p1404
Menopausal hormone therapy and dementia
Conflict of interest statement
Competing interests: The BMJ has judged that there are no disqualifying financial ties to commercial companies. The authors declare the following other interests: Dr Kantarci was involved in an unpaid educational activity on Alzheimer’s disease for Biogen Inc. and is the PI on a study of a PET imaging ligand for Alzheimer's disease, to which Eli Lilly and Avid Radiopharmaceuticals, donated supplies. She is funded by the National Institutes of Health (NIH) and Alzheimer’s Drug Discovery Foundation (ADDF). Dr Manson reports no relevant disclosures.
Comment in
-
Menopausal hormone therapy and dementia: causal link remains uncertain rather than unlikely.BMJ. 2023 Aug 2;382:1776. doi: 10.1136/bmj.p1776. BMJ. 2023. PMID: 37532282 No abstract available.
Comment on
-
Menopausal hormone therapy and dementia: nationwide, nested case-control study.BMJ. 2023 Jun 28;381:e072770. doi: 10.1136/bmj-2022-072770. BMJ. 2023. PMID: 37380194 Free PMC article.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical